• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Clarus Ventures

edit

Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds

Milestones

edit

• 
  Clarus Ventures invested in Catabasis Pharmaceuticals. (12/13/11)
  Posted 12/13/11 at 7:37pm via catabasispharma.com
• 
  Clarus Ventures invested in NanoString Technologies. (11/7/11)
  Posted 11/7/11 at 5:45am via xconomy.com
• 
  Clarus Ventures invested in Cleave Biosciences. (10/11/11)
  Posted 10/11/11 at 7:32pm via finsmes.com
• 
  Clarus Ventures invested in Restoration Robotics. (8/3/11)
  Posted 8/3/11 at 5:52pm via finsmes.com
• 
  Clarus Ventures invested in SARcode Bioscience. (7/18/11)
  Posted 7/18/11 at 5:31pm via finsmes.com
• 
  Clarus Ventures invested in Aerie Pharmaceuticals. (3/7/11)
  Posted 3/3/11 at 8:43pm via aeriepharma.com
• 
  Clarus Ventures invested in TyRx Pharma. (12/8/10)
  Posted 12/8/10 at 7:28pm via tyrx.com
• 
  Clarus Ventures invested in Zogenix. (7/13/10)
  Posted 10/31/10 at 7:28pm via zogenix.com
• 
  Clarus Ventures invested in Achillion Pharmaceuticals. (8/18/10)
  Posted 10/31/10 at 6:24pm via achillion.com
• 
  Clarus Ventures invested in TetraLogic Pharmaceuticals. (8/10/10)
  Posted 8/10/10 at 5:26pm via fiercebiotech.com
• 
  Clarus Ventures invested in NanoString Technologies. (2/12/10)
  Posted 7/20/10 at 7:02pm
• 
  Clarus Ventures invested in FerroKin Biosciences. (6/18/10)
  Posted 6/20/10 at 3:37am via fiercebiotech.com
• 
  Clarus Ventures invested in Oxford Immunotec. (5/4/10)
  Posted 5/5/10 at 8:13pm via onbiovc.com
• 
  Clarus Ventures invested in Catabasis Pharmaceuticals. (4/21/10)
  Posted 4/21/10 at 6:05pm via fiercebiotech.com
• 
  Clarus Ventures invested in SARcode Bioscience. (12/1/06)
  Posted 4/21/10 at 1:31am via sarcode.com
• 
  Clarus Ventures invested in Zogenix. (8/28/06)
  Posted 4/19/10 at 9:15pm via zogenix.com

Investments

Videos

Sources

1. Catabasis Pharmaceuticals Announces $8 Million Series A Extension Financing (catabasispharma.com) [edit]
2. NanoString Grabs $20M From GE, Former Genzyme CEO to Pursue Molecular Diagnostics (xconomy.com) [edit]
3. Cleave Biosciences Raises $42M in Series A Financing (finsmes.com) [edit]
4. Restoration Robotics Raises $41M in Series C Financing (finsmes.com) [edit]
5. SARcode Bioscience Closes $44M Series B Financing (finsmes.com) [edit]
6. Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio (aeriepharma.com) [edit]
7. TYRX, Inc. Raises $20 Million in Private Financing (tyrx.com) [edit]
8. Achillion Announces Private Placement of $50 Million (ir.achillion.com) [edit]
9. TetraLogic nabs $32M round for lead cancer therapy Read more: TetraLogic nabs $32M round for lead cancer therapy (fiercebiotech.com) [edit]
10. Zogenix Secures $35 Million Debt Facility And Raises $15 Million Investment Capital (zogenix.com) [edit]
11. FerroKin rounds up $12M for iron overload treatment Read more: FerroKin rounds up $12M for iron overload treatment - FierceBiotech http://www.fiercebiotech.com/story/ferrokin-rounds-12m-iron-overload-treatment/2010-06-18?utm_medium=rss&utm_source=rss#ixz (fiercebiotech.com) [edit]
12. Oxford Immunotec, Ltd.: Series D $26M (onbiovc.com) [edit]
13. Catabasis lands $39M Series A for diabetes programs (fiercebiotech.com) [edit]
14. Pearl Therapeutics, Inc.: Series C $15M (onbiovc.com) [edit]
15. Cap funding Report [edit]
16. Neomend Closes $30M Funding Round (finsmes.com) [edit]
17. Ophthotech nabs $30M round to fund AMD trial (fiercebiotech.com) [edit]
18. Virdante Pharmaceuticals, Inc.: Series A $30M (onbiovc.com) [edit]
19. SEC D (sec.gov) [edit]
20. NANOSTRING® TECHNOLOGIES CLOSES $30 MILLION SERIES C FINANCING TO ACCELERATE THE COMMERCIALIZATION OF ITS LEADING EXPRESSION PROFILING PRODUCTS (freshnews.com) [edit]
21. Lycera Corp.: Series A $36M (onbiovc.com) [edit]
22. Aerovance inhales $38M for asthma drugs (venturebeat.com) [edit]
23. Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C (mitsuiventures.com) [edit]
24. ESBATech rounds up $22M in second round (fiercebiotech.com) [edit]
25. Pearl Therapeutics ups its first round funding (deals.venturebeat.com) [edit]
26. Zogenix Raises $18 Million in Preferred Stock Financing (zogenix.com) [edit]
27. Taligen Therapeutics Secures Series B Financing (taligentherapeutics.com) [edit]
28. Pelikan Tech to push “finger friendly” diabetes testing (venturebeat.com) [edit]
29. Oxford Immunotec Completes $40M Financing (oxfordimmunotec.com) [edit]
30. Sientra, device maker for plastic surgery, raises $85M (deals.venturebeat.com) [edit]
31. Aerovance, asthma treatment company, finishes raising $60M (deals.venturebeat.com) [edit]
32. Variation Biotechnologies Secures US$35.7 Million in Series A Financing to Fund Innovative Vaccine Platform (variationbiotech.com) [edit]
33. SARcode secured $25 million in financing (sarcode.com) [edit]
34. Zogenix, Inc. Raises $60 Million In Series A Venture Financing; Names Board of Directors (zogenix.com) [edit]
35. ESBATech Closes USD 41M Series B Venture Financing (esbatech.com) [edit]